Buy Saxenda

Saxenda® is injected once a day at any time, regardless of food intake. It should be injected into the abdomen, thigh or shoulder area. The place and time of injection can be changed without dose correction. However, it is recommended to give injections at about the same time of day after choosing the most convenient time.

 

 

Doses

 

The initial dose is 0.6 mg per day. The dose is increased to 3 mg per day, adding 0.6 mg at intervals of at least one week to improve gastrointestinal tolerance. If the new dose is not well tolerated for 2 consecutive weeks when the dose is increased, consideration should be given to discontinuing therapy. Use of the drug in a daily dose exceeding 3 mg is not recommended.

 

The therapy with Saxenda® should be discontinued if after 12 weeks of using the preparation in a dose of 3 mg per day the loss in body weight was less than 5% of the initial value. The need to continue therapy should be reviewed annually.

 

 

Missed dose

 

If less than 12 hours have elapsed after the normal dose time, the patient should administer the dose as soon as possible. If less than 12 hours have elapsed before the normal time of the next dose, the patient should not give a missed dose but should resume injection at the next scheduled dose.

No additional or increased dose should be given to compensate for a missed dose.

 

 

Patients with diabetes mellitus type 2

 

Saxenda® should not be used in combination with other EPP-E receptor agonists.

At the beginning of therapy with Saxenda® it is recommended to reduce the doses of simultaneously applied insulin secretogens (such as sulfonyl-urea preparations) to reduce the risk of hypoglycemia.

 

Elderly patients (≥ 65 years)

 

No age-related dose adjustments are required. Experience with the drug in patients ≥ 75 years of age is limited, use of the drug in these patients should be with caution.

 

 

Patients with renal failure

 

In patients with mild to moderate renal impairment (creatinine clearance ≥ 30 ml/min) no dose correction is required.

There is limited experience with Saxenda® in patients with severe renal impairment (creatinine clearance ≥ 30 ml/min). The use of Saxenda® in such patients, including patients with terminal renal failure, is contraindicated.

 

 

Patients with liver dysfunction​​​​​​​

 

For patients with mild to moderate liver dysfunction, use with caution.

The use of Saxenda® in patients with severe liver dysfunction is contraindicated.

 

 

Children

 

The use of Saxenda® for children and adolescents under 18 is contraindicated due to the lack of data on safety and efficiency.

You may watch an video instruction for a better understanding of the process of injection by clicking this link.

 

• Inject your dose of Saxenda® under the skin (subcutaneous injection) in your stomach area (abdomen), upper leg (thigh), or upper arm, as instructed by your health care provider. Do not inject into a vein or muscle!

 

• Never share your Saxenda® pen or needles with another person. You may give an infection to them, or get an infection from them.

 

• Saxenda® cannot be used if it has been frozen.

 

• Saxenda® can be injected with up to 8 mm long needles. The pen syringe is intended for use with disposable needles NovoFine® or NovoTwist®.

 

• Injection needles are not included in the packaging.
   

• Hypersensitivity to liraglutide or any of the drug's auxiliary components;

 

• medullary thyroid cancer in the history, including the family;

 

• type 2 multiple endocrine neoplasia;

 

• severe depression, suicidal ideation or behaviour, including in a history.

 

 

Use is contraindicated in the following groups of patients and in the following conditions/diseases due to lack of data on efficacy and safety:

• severe renal impairment;

 

• dysfunction of the liver of severe degree;

 

• children under 18 years of age;

 

• period of pregnancy and breastfeeding;

 

• heart failure of functional class III-IV (according to the classification of NYHA (New York Cardiology Association));

 

• simultaneous use of other drugs for body weight correction;

 

• simultaneous use with insulin;

 

• secondary obesity against the background of endocrinological diseases or eating disorders, or against the background of the use of medications that may lead to weight gain.

 

 

Experience of using Saxenda® in patients with inflammatory bowel disease and diabetic paresis of the stomach is limited. Lyraglutide use for such patients is not recommended as it is associated with transient undesirable reactions from the gastrointestinal tract, including nausea, vomiting and diarrhea.

 

 

Be careful:

 

Patients with chronic heart failure class I-II according to the NYHA classification, mild to moderate liver function disturbance, pancreatitis in history, thyroid disease; patients ≥ 75 years old.

Patients reported that overdoses were accompanied by severe nausea, vomiting and diarrhoea, but in all cases the condition of patients recovered without complications. There was no severe hypoglycemia in any of the cases.

In case of overdose, appropriate symptomatic therapy should be performed.

GPP-1 is an intestinal hormone that is actively released after a meal. It is responsible for a sense of satiety, reducing the feeling of hunger, and thus the regulation of appetite. In addition, GPP-1 stimulates the release of insulin and inhibition of glucagon synthesis corresponding to blood glucose concentration.

 

Saxenda®  is an analogue of glucagone-like peptide-1 (GPP-1), 97% identical to the natural human GPP-1. Saxenda® is the first of its kind to be registered for use in obesity therapy in the USA, Canada, EU and Russia on the basis of GPP-1. Today the product is available in more than 45 countries.

 

The drug is injected subcutaneously using a handy multi-dose automatic syringe handle. The active substance, entering the blood, activates GPP-1 receptors in the brain and causes a feeling of dryness. Thus, taking Saxenda® once a day reduces appetite and, consequently, the amount of food consumed.

 

Saxenda ® not only reduces the waist circumference, but also the volume of visceral fat, which is important for secondary prevention of complications. Thus, in addition to its direct action, the drug reduces blood pressure figures in hypertension, reduces blood cholesterol levels, facilitates night apnea symptoms.

The efficacy and safety of Saxenda® has been carefully studied in extensive clinical trials. 

 

Studies involving 5,000 patients observed between 6 months and three years showed that approximately 90% of patients who took the drug regularly resulted in weight loss. 56 weeks of medication combined with diet and exercise resulted in a 9.2% weight loss.

 

Significant results of the study:

 

• Weight loss of 5% or more in 63 percent of patients treated with Saxenda® versus 27 percent in the placebo group.

 

• Weight loss by 10% or more in 33% of patients in the group on therapy with Saxenda® versus 11% in the placebo group.

 

• Reduction of blood glucose level at initially elevated figures (prediabetes) in obese patients against the background of Saxenda®.

 

• Saxenda® was well tolerated. Slight side effects of the gastrointestinal tract were transient and disappeared within 4 weeks

The list of undesirable reactions recorded during clinical trials is presented below. Unwanted reactions are grouped according to the MedDRA organ systems and frequency. Frequency is defined as: very often (≥1/10); often (≥1/100 to <1/10); not often (≥1/1000 to <1/100); rarely (≥1/10000 to <1/1000); very rarely (<1/10000).

 

 

The immune system: rarely - anaphylactic reactions.

 

The metabolic and nutritional side: often - hypoglycemia; rarely - dehydration.

 

Psychiatric disorders: often - insomnia.

 

Nervous system: often - dizziness, dysgeusia.

 

Heart disorders: rarely - tachycardia.

 

Gastrointestinal tract: very often - nausea, vomiting, diarrhea, constipation; often - dry mouth, dyspepsia, gastritis, gastroesophageal reflux, pain in the upper abdomen, flatulence, belching, bloating; not often - pancreatitis.

 

Liver and biliary tract: often - cholecystitis; not often - cholecystitis.

 

Skin and subcutaneous tissues: not often - hives.

 

Kidney and urinary tract: rarely - acute kidney failure, renal function disorders.

 

General disorders and disorders at the place of administration: often - reactions at the place of administration, asthenia, fatigue; not often - malaise.

 

Laboratory methods of investigation: often - increase in lipase activity, increase in amylase activity.

At 2-8 °C.

In the fridge, but not near the freezer.

Store the used syringe pen with the product at a temperature no higher than 30 °C or in the refrigerator (at 2 °C to 8 °C).

Do not freeze.

Use for 1 month. Cover the pen syringe with a cap to protect against light.

 

Keep it out of the reach of children.

 

 

Shelf life: 30 months.

In 1 ml of the preparation is contained:

active ingredient: liraglutide 6 mg (one pre-filled syringe handle contains 3 ml of solution, which corresponds to 18 mg liraglutide);
auxiliary substances: sodium hydrophosphate dihydrate 1.42 mg, phenol 5.5 mg, propylene glycol 14.0 mg;

hydrochloric acid/sodium hydroxide (for pH correction), water for injections up to 1 ml.

You can buy Saxenda from our website absolutely legally.

Delivery is carried out to all countries in the world, which do not have an official ban on receiving and sending mail (mainly island countries).

We guarantee that you will receive your parcel with Saxenda without any problems at customs (we have our own delivery channels to countries with strict customs).

We guarantee a refund if your package has not been delivered to you for any reason, according to PayPal protection policy.

Due to Quarantine, delivery time may increase slightly, but still delivery remains within reasonable limits and does not exceed the delivery time during Christmas sales.

There is no prescription required!

You can legally buy Saxenda on our website without prescription!

Full Description on English (PDF)